Project Grant R01HL178832
Award Date
5/1/25
Completion Date
2/28/30
Dollars Obligated
$735K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to functionally characterize the endothelial cell niche for hematopoietic stem cells. The $696,870 grant, awarded on Aug 1, 2024, will enable The Children's Hospital Corporation, doing business as Boston Children's Hospital, to examine vascular reprogramming in adults...
This $642,754.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to understand the mechanisms behind hematopoietic stem cell (HSC) functional decline after bone marrow transplantation. The key objectives are to: 1) investigate why abnormal mitochondria in HSCs are not removed after transplantation and the impact on HSC functions, and 2) explore the effects of mitochondrial defects on...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $130,337 to The Trustees of Columbia University in the City of New York to investigate the intrinsic and extrinsic factors regulating hematopoietic stem cell (HSC) function and the interplay between HSC biology and immunology. The project aims to characterize the cellular components of the HSC niche in the liver during...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357 in funding to Childrens Hospital Medical Center in Cincinnati, Ohio to conduct research on the bone marrow microenvironment and its role in blood cell production. The key objectives of this research program are to: 1) Dissect the function of specialized microenvironments that serve as niches for different blood cell...
The $814,209 federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop a novel nanoparticle-based gene therapy approach for in vivo hematopoietic stem cell (HSC) modification. The project aims to optimize nanoparticle formulations that can deliver next-generation gene-editing agents and target the HSC-enriched cell population identified in the researchers' prior...
This Project Grant award in the amount of $493,810 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding supports research at the University of Wisconsin-Madison to investigate the role of cellular interactions and microenvironmental signals in programming hematopoietic stem and progenitor cells (HSPCs) during development and migration. Specific aims include determining how vascular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $773,257 to St. Jude Children's Research Hospital to investigate the mechanisms of lysosome segregation and cell fate regulation in dividing hematopoietic stem cells (HSCs). The research project aims to identify factors regulating lysosome segregation during HSC division and examine how the RhoGTPases CDC42 and RAC influence...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to better understand the signaling and metabolic processes that allow hematopoietic stem cells (HSCs) to self-renew and avoid oxidative damage under hypoxic conditions in the bone marrow. The central goal is to explore methods to manipulate these processes in normoxic conditions in order to improve the functionality of HSCs for...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award of $889,998 under CFDA 93.837 (Cardiovascular Diseases Research) aims to develop a novel alpha-retroviral vector-based technology platform for in vivo and ex vivo delivery of genetic therapies to hematopoietic stem cells (HSCs). The key objectives are to: (I) develop integrating vectors to deliver a curative transgene to HSCs in vivo to treat X-linked severe combined immunodeficiency (X-SCID); (II) engineer virus-like...
This $375,988 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to examine the interactions between endothelial cells and mural cells in capillary malformations. The principal investigator will use human endothelial cells expressing the R183Q mutation in the GNAQ gene, which is linked to capillary malformations, to (1) identify paracrine interactions between these mutant endothelial...